Preclinical is the bucket where peptide research lives between mechanism and the clinic. Coverage on this site has tracked rodent, pig, and non-human-primate readouts for compounds that are not yet in human trials but carry the strongest claims about the next generation of peptide therapeutics.
Lead programs covered here in 2026: the Lilly + Indiana Biosciences quintuple agonist (GLP-1/GIP/glucagon/amylin/calcitonin) with rodent data heading to ADA 2026 May 29, the DiMarchi/Tschöp/Müller GLP-1R/GIPR/PPARα/γ/δ peptide-drug conjugate published in Nature April 30, the BMC Biotechnology DualPep-ALO cell-penetrating peptide for hair growth, the Aivocode CAQK tetrapeptide for traumatic brain injury (EMBO Mol Med, October 2025), the UTHealth BLMP6 fibulin-4 peptide for metastatic triple-negative breast cancer, and the early atherosclerotic-plaque-prevention work with GLP-1.
Stories here cover animal-model efficacy, mechanism-of-action work, and IND-enabling readouts. See #animal-models, #mechanism, and #ind for adjacent threads.
A Johns Hopkins Bloomberg School of Public Health team reported in npj Antimicrobials and Resistance on October 13, 2026 a genome survey of Anopheles gambiae, the main African malaria mosquito, that identified 36 previously uncharacterized antimicrobial peptide candidates. Lab-made versions of four, named Anolarvin, Konopsin, Sialicin, and Cryptophelin, killed or stopped a broad range of microbes, and the two found mainly in salivary glands, Sialicin and Cryptophelin, reduced the viability of Plasmodium falciparum sporozoites, the parasite stage mosquitoes inject, by about 81% and 75% in lab tests. The authors see them as leads for blocking malaria transmission.
Researchers at the Feinstein Institutes for Medical Research reported in Frontiers in Immunology on October 12, 2026 that OP18, an opsonic peptide that tags damage signals such as histone H3 and HMGB1 for removal, increased the uptake of macrophage extracellular traps, sticky webs that radiation-damaged immune cells release, through the αvβ3 integrin. Clearing the traps eased mitochondrial stress in macrophages, raised the anti-inflammatory signal IL-10, and showed a trend toward lower NF-κB activation. The results come from cell experiments only.
Researchers at Nanjing Drum Tower Hospital and Jiangnan University-affiliated Wuxi Fifth Hospital reported in Cell Death Discovery on October 10, 2026 that high blood sugar lowered levels of MOTS-c, a small peptide encoded in mitochondrial DNA, in retinal blood vessels. MOTS-c treatment protected the vessel barrier and mitochondrial function in human retinal endothelial cells exposed to high glucose and in diabetic mice, and blocking the enzyme PLA2G6 erased that protection. MOTS-c is one of the peptides the FDA's compounding advisers voted to recommend in July 2026, but this work is in cells and mice.
Researchers from the University of Texas Medical Branch, Rush University Medical Center, and partners in Germany reported in Molecular Biomedicine on October 9, 2026 a 19-amino-acid peptide, hICOSL-19, based on the immune protein ICOSL, that blocks αvβ3 integrin, a receptor whose overactivity damages podocytes, the cells that form the kidney's filter. A longer-lasting PEGylated version reduced protein in the urine, limited kidney damage, and preserved podocyte structure in mouse models of immune-mediated glomerulonephritis and diabetic kidney disease, without signs of T-cell activation or anti-drug antibodies. The results are from mice and cells.
University of Zurich researchers reported in Science Advances on October 9, 2026 that red blood cells coupled to the disease-inducing peptide prevented experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis, when given beforehand and eased symptoms when given after onset. The effect was specific to the coupled peptide and depended on both cell and peptide dose. Kupffer cells, immune cells in the liver that swallowed the coated red cells, were required for tolerance. The authors describe red cells coupled to a cocktail of multiple sclerosis peptides as a promising approach for patients, but these results are from mice.
Researchers at Fujian Medical University reported in Bioconjugate Chemistry on October 8, 2026 that they used the PepMimic AI platform to design TR23, a peptide designed by mimicking a protein binding interface, and labeled it with gallium-68 for PET imaging. The tracer bound TROP-2, a protein common in many solid tumors and the target of the antibody-drug conjugate Trodelvy, with nanomolar strength, and gave clear, specific tumor signals in pancreatic, prostate, and thyroid cancer models in mice, with signal strength tracking TROP-2 levels in tissue. The work is preclinical.
Researchers at Zhejiang University of Technology in China and Egypt's National Research Centre reported in the Journal of Medicinal Chemistry on October 7, 2026 a deep-learning model, SMAMP, that reads peptides as full chemical structures, so it can handle unnatural amino acids and end-group changes that sequence-based models miss. Of 19 very short peptides designed with its help, 13 killed bacteria, and the model's predicted potency against E. coli tracked lab measurements (correlation 0.764). Two leads, HP-1 and HP-2, were strongly bactericidal with low toxicity to mammalian cells, led to less resistance than standard antibiotics in lab tests, protected wax moth larvae from infection, and helped wounds heal in mice.
Researchers at Kumamoto University in Japan reported in Molecular Pharmaceutics on October 7, 2026 a small ring-shaped peptide, called SLS, that can be built into an antibody's genetic code to help it reach the brain. Attaching one SLS peptide to each heavy chain of the breast cancer antibody trastuzumab increased its passage across lab models of the blood-brain barrier and raised its brain levels after intravenous injection in mice, while its blood levels and its ability to kill HER2-positive cancer cells stayed about the same. The tag also raised brain delivery of the Alzheimer's antibody aducanumab; the work so far is in cells and mice.
Researchers at Lembas Bio and Tel Aviv University reported in ACS Nutrition Science on October 6, 2026 an AI-guided design pipeline, built on AlphaFold2 structural modeling, for peptides that act on nutrient-sensing receptors of the gut cells that release the hormone GLP-1. After four rounds of design and screening, lead peptides raised GLP-1 secretion more than 27-fold in a mouse gut cell line, exceeding an optimized small-molecule GLP-1 secretagogue, and 28 days of oral dosing reduced food intake and body weight in diet-induced obese rats, with semaglutide as an active comparator. The authors present the work as a route to nutritional ingredients, and the results so far come from cells and rats.
A University of Pennsylvania psychiatry team reported in Diabetes, Obesity and Metabolism on October 6, 2026 that neurons carrying the amylin-responsive calcitonin receptor in the laterodorsal tegmental nucleus, a brainstem region tied to reward and motivation, project to the ventral tegmental area in both mice and rats. Knocking down the receptor along that pathway weakened the appetite-suppressing effect of injected salmon calcitonin, which activates amylin receptors, and chemically switching the pathway on reduced food intake and body weight in mice. The findings come from rodents and help explain how amylin signaling reduces food intake.
Researchers at Nanjing Agricultural University reported in Aging Cell, published online Friday, October 2, 2026, that elamipretide increased litter size in aged female mice and improved the quality and maturation of their eggs, an effect they traced to a vitamin B6 and VEGF signaling pathway. In lab experiments, the peptide also improved the maturation, fertilization, and early cell division of eggs from older women. Elamipretide received FDA accelerated approval as Forzinity for the rare mitochondrial disease Barth syndrome in September 2025, and it has not been tested as a fertility treatment in people.
Researchers at the University of Hong Kong and BayVax Biotech reported in Advanced Science on Friday, October 2, 2026 a vaccine platform called SaPAC that chemically links neoantigen peptides to the TLR7-activating adjuvant 1V209, so the conjugates assemble into nanoparticles of about 100 to 200 nm. In mice, the particles reached lymph nodes better than peptide nanoparticles mixed with free adjuvant, and SaPAC alone slowed tumor growth in melanoma and bladder cancer models. In a triple-negative breast cancer model, combining multivalent SaPAC with anti-PD-1 therapy gave durable tumor suppression comparable to a Poly(I:C)-adjuvanted benchmark without detectable systemic toxicity; all results come from mice.
Researchers at Harbin Medical University reported in CNS Neuroscience & Therapeutics, published online October 1, 2026, that B9, a peptide derived from the viral protein apoptin, lowered seizure susceptibility, reduced epileptiform activity on EEG, and improved spatial learning and memory in mouse models of acute seizures and kainic acid-induced temporal lobe epilepsy. The team traced the effect to B9 suppressing the heat shock protein HSPA1A and freeing the protein AP2B1, which preserved the glutamate receptor subunit GluA2 and limited calcium overload in neurons; knocking down AP2B1 erased B9's benefits. The findings come from mice only.
Ascletis Pharma announced on Friday, October 2, 2026 preclinical data presented at EASD for ASC36_35FDC, a fixed-dose injection that combines its peptide amylin receptor agonist ASC36 with its peptide GLP-1/GIP receptor agonist ASC35. In non-human primates, the two components had half-lives of about 781 hours (33 days) and 721 hours (30 days), which the company says could support once-monthly and possibly once-quarterly dosing in people. In diet-induced obese rats, the combination cut body weight 24.8% at day 14 versus 12.5% for an eloralintide/tirzepatide combination and 16.8% for MET-233i/tirzepatide at the same dosing; the results come from animals only.
A study in the International Journal of Obesity compared semaglutide, tirzepatide, and retatrutide in MC4R-knockout mice, a model of the most common monogenic obesity. Over 21 days, mean body-weight reduction reached 31.6% with tirzepatide, 24.1% with retatrutide, and 19.7% with semaglutide, and tirzepatide also suppressed cumulative food intake most aggressively. All three improved plasma insulin, HOMA-IR, cholesterol, and liver-damage markers, suggesting incretin drugs can drive weight loss even when the POMC-MC4R satiety axis is disrupted.
Eli Lilly, with the Indiana Biosciences Research Institute, has disclosed an ADA Scientific Sessions Late-Breaking Poster slot (Poster 2839-LB, May 29) for a single peptide molecule that simultaneously activates five receptors: GLP-1, GIP, glucagon, amylin, and calcitonin. Lead investigator Jonathan Douros, PhD, will present rodent data showing weight-loss superiority over retatrutide in Lilly-sponsored animal studies. The compound is distinct from the DiMarchi/Tschöp/Müller GLP-1R/GIPR/PPARα/γ/δ quintuple agonist published in Nature on April 30 — that one is a peptide-drug conjugate combining GLP-1/GIP with the pan-PPAR agonist lanifibranor, while the Lilly + Indiana Biosciences molecule appears to be a single peptide hitting all five receptors directly. Both signal that the obesity-pharmacology ceiling is moving past the triple-agonist generation.
A 2026 BMC Biotechnology paper introduces DualPep-ALO, a novel synthetic cell-penetrating peptide engineered to promote hair growth by restoring the follicular microenvironment and stimulating regenerative pathways. In preclinical models, DualPep-ALO showed potent antioxidant, anti-inflammatory, and pro-regenerative effects, restoring follicular vitality through multimodal biological pathways. The paper supports the peptide's potential as a topical CPP-based agent for hair loss, warranting further clinical investigation. The work joins a 2026 wave of peptide-led hair-growth research alongside copper-peptide GHK-Cu's surge in the cosmetic and longevity-clinic space and the broader 'peptide therapy' search trend that Drexel's May 5 Q&A flagged as a 1,016% YoY rise for GHK-Cu specifically.
A study in Scientific Reports found that early intervention with tirzepatide or semaglutide significantly reduced atherosclerotic plaque formation in ApoE-knockout mice, suggesting GLP-1 drugs may have preventive cardiovascular benefits beyond their metabolic effects when initiated before disease progression.